Epanova regulatory update

AstraZeneca said FDA accepted for review an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. The PDUFA date is May 5, 2014. Epanova is an ultra-pure mi...